Skip to main content
. 2021 Mar 15;5(6):1695–1705. doi: 10.1182/bloodadvances.2020003531

Table 3.

CRS and NE characteristics (N = 127)

Grade* n (%) Median (range) n (%)
CRS onset, d CRS resolution, d NE onset, d NE resolution, d CRS onset before NE NE onset before CRS Same onset
CRS only
 Any 47 (37.0) 5.0 (1.0-14.0) 9.0 (2.0-17.0)
 1 33 (26.0) 5.0 (2.0-14.0) 8.0 (2.0-17.0)
 2 13 (10.2) 5.0 (1.0-9.0) 9.0 (6.0-15.0)
 ≥3 1 (0.8) 3.0 (3.0-3.0) 8.0 (8.0-8.0)
NE only
 Any 14 (11.0) 10.0 (2.0-34.0) 20.0 (7.0-94.0)
 1 4 (3.1) 12.5 (8.0-20.0) 23.5 (18.0-32.0)
 2 3 (2.4) 17.0 (14.0-20.0) 20.0 (20.0-20.0)
 ≥3 7 (5.5) 8.0 (2.0-34.0) 19.0 (7.0-94.0)
Nonconcurrent CRS and NE
 Any 21 (16.5) 4.0 (1.0-11.0) 9.0 (2.0-19.0) 13.0 (6.0-66.0) 25.0 (6.0-92.0) 21 (100.0) 0 0
 CRS and NE ≤2 16 (12.6) 3.0 (1.0-7.0) 9.0 (2.0-19.0) 14.5 (6.0-66.0) 27.5 (6.0-92.0) 16 (100.0) 0 0
 CRS or NE ≥3 5 (3.9) 6.0 (3.0-11.0) 12.0 (8.0-13.0) 13.0 (9.0-15.0) 23.0 (22.0-55.0) 5 (100.0) 0 0
Concurrent CRS and NE
 Any 45 (35.4) 4.0 (1.0-12.0) 10.0 (3.0-24.0) 7.0 (1.0-18.0) 16.0 (3.0-90.0) 31 (68.9) 8 (17.8) 6 (13.3)
 CRS and NE ≤2 29 (22.8) 5.0 (2.0-8.0) 10.0 (3.0-24.0) 7.0 (1.0-16.0) 14.0 (3.0-42.0) 20 (69.0) 6 (20.7) 3 (10.3)
 CRS or NE ≥3 12 (9.4) 4.0 (1.0-12.0) 11.5 (6.0-23.0) 8.0 (1.0-18.0) 18.0 (12.0-90.0) 8 (66.7) 2 (16.7) 2 (16.7)
 CRS and NE ≥3 4 (3.1) 4.0 (3.0-8.0) 12.5 (9.0-16.0) 5.5 (4.0-12.0) 12.5 (25.0-30.0) 3 (75.0) 0 1 (25.0)
Any CRS 113 5.0 (1.0-14.0) 9.0 (2.0-24.0)
Any NE 80 9.0 (1.0-66.0) 19.0 (3.0-94.0)
*

Lee et al12 criteria were used to determine CRS toxicity grade, and National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03)17 were used to determine NE toxicity grade.

Percentages based on patients who experienced a CRS and/or NE episode.

Percentages calculated within each row.